EMA Application withdrawn: Xyndari — Emmaus Medical Europe Ltd

View source ↗

Summary

EMA withdrew the application for Xyndari by Emmaus Medical Europe Ltd in the orphan medicine program for anemia and sickle cell disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Sickle Cell Disease

Drugs mentioned

• Xyndari

Snippet

Status: Application withdrawn. Therapeutic area: Anemia, Sickle Cell. MAH: Emmaus Medical Europe Ltd. Orphan medicine